Search This Blog

Friday, May 27, 2016

Kyprolis® (Carfilzomib) Demonstrates Economic Value In Relapsed Or Refractory Multiple Myeloma Manuscript Published In "Journal of Medical Economics"

Analysis Based on Head-to-Head Trial Shows Kyprolis With Lenalidomide and Dexamethasone Offers Substantial Value Over Previous Standard of Care in Relapsed or Refractory Multiple Myeloma



Amgen - Investors - RSS Content

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.